Your browser doesn't support javascript.
loading
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Colleoni, Marco; Luo, Weixiu; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Hitre, Erika; Graas, Marie-Pascale; Simoncini, Edda; Kamby, Claus; Thompson, Alastair; Loibl, Sibylle; Gavilá, Joaquín; Kuroi, Katsumasa; Marth, Christian; Müller, Bettina; O'Reilly, Seamus; Di Lauro, Vincenzo; Gombos, Andrea; Ruhstaller, Thomas; Burstein, Harold; Ribi, Karin; Bernhard, Jürg; Viale, Giuseppe; Maibach, Rudolf; Rabaglio-Poretti, Manuela; Gelber, Richard D; Coates, Alan S; Di Leo, Angelo; Regan, Meredith M; Goldhirsch, Aron.
Afiliación
  • Colleoni M; International Breast Cancer Study Group, Milan, Italy; Division of Medical Senology, Milan, Italy. Electronic address: marco.colleoni@ieo.it.
  • Luo W; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Karlsson P; International Breast Cancer Study Group and Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Chirgwin J; International Breast Cancer Study Group, Australia and New Zealand Breast Cancer Trials Group, and Box Hill and Maroondah Hospitals, Monash University, Melbourne, VIC, Australia.
  • Aebi S; International Breast Cancer Study Group and Lucerne Canton Hospital, Lucerne, Switzerland.
  • Jerusalem G; International Breast Cancer Study Group, Centre Hospitalier Universitaire de Liège, Liège University, Liège, Belgium.
  • Neven P; International Breast Cancer Study Group and Multidisciplinary Breast Center, University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Hitre E; International Breast Cancer Study Group and National Institute of Oncology, Budapest, Hungary.
  • Graas MP; International Breast Cancer Study Group and Centre Hospitalier Chrétien Clinique St Joseph, Liège, Belgium.
  • Simoncini E; International Breast Cancer Study Group and ASST Spedali Civili di Brescia, Brescia, Italy.
  • Kamby C; Danish Breast Cancer Group and Rigshospitalet, Copenhagen, Denmark.
  • Thompson A; Scottish Cancer Trials Breast Group and The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Loibl S; German Breast Group, Neu-Isenburg, Germany.
  • Gavilá J; SOLTI Group and Fundación Instituto Valenciano de Oncologia, Valencia, Spain.
  • Kuroi K; Japan Breast Cancer Research Group and Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Marth C; Austrian Breast & Colorectal Cancer Study Group and Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria.
  • Müller B; Chilean Cooperative Group for Oncologic Research, Providencia, Santiago, Chile.
  • O'Reilly S; Cancer Trials Ireland and Cork University Hospital, Cork, Ireland.
  • Di Lauro V; International Breast Cancer Study Group and Centro di Riferimento Oncologico di Aviano, Aviano, Italy.
  • Gombos A; Medical Oncology Clinic, Institute Jules Bordet, Brussels, Belgium.
  • Ruhstaller T; Swiss Group for Clinical Cancer Research, International Breast Cancer Study Group, and Breast Center St Gallen, St Gallen, Switzerland.
  • Burstein H; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Ribi K; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
  • Bernhard J; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Bern University Hospital, Inselspital, Bern, Switzerland.
  • Viale G; European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group Central Pathology Office and University of Milan, Milan, Italy.
  • Maibach R; International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
  • Rabaglio-Poretti M; International Breast Cancer Study Group, Inselspital, Bern, Switzerland; Bern University Hospital, Inselspital, Bern, Switzerland.
  • Gelber RD; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Harvard T H Chan School of Public Health, Boston, MA, USA; Frontier Science & Technology Research Foundation, Boston, MA, USA.
  • Coates AS; International Breast Cancer Study Group and University of Sydney, Sydney, NSW, Australia.
  • Di Leo A; International Breast Cancer Study Group and Hospital of Prato-AUSL Toscana Centro, Istituto Toscano Tumori, Prato, Italy.
  • Regan MM; International Breast Cancer Study Group Statistical Center, Boston, MA, USA; Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
  • Goldhirsch A; International Breast Cancer Study Group, Milan, Italy; European Institute of Oncology, Milan, Italy.
Lancet Oncol ; 19(1): 127-138, 2018 01.
Article en En | MEDLINE | ID: mdl-29158011
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_breast_cancer Asunto principal: Triazoles / Neoplasias de la Mama / Posmenopausia / Inhibidores de la Aromatasa / Antineoplásicos / Nitrilos Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 6_ODS3_enfermedades_notrasmisibles Problema de salud: 6_breast_cancer Asunto principal: Triazoles / Neoplasias de la Mama / Posmenopausia / Inhibidores de la Aromatasa / Antineoplásicos / Nitrilos Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article